Novel Nanoliposomes Alleviate Contrast-induced Acute Kidney Injury in New Zealand Rabbits by Mediating Inflammatory Response
Overview
Authors
Affiliations
Background: The purpose of the research was to investigate the preventive effect of nanoliposomes on contrast-induced nephropathy (CIN) in New Zealand rabbits and to provide a theoretical basis for clinically effective prevention and treatment of CIN and the development of new contrast agents.
Methods: A total of 48 New Zealand rabbits were divided into four groups randomly, there were 12 rabbits in eacj group: (I) control group; (II) contrast group; (III) hydration prevention group; and (IV) nanoliposome group. The changes of serum creatinine (SCr) and blood urea nitrogen (BUN) were messured before and after injection of iopromide. Enzyme-linked immunosorbent assay (ELISA) was used to detect inflammatory and oxidative stress indexes, including neutrophil gelatinase-associated lipoprotein (NGAL), tumor necrosis factor-α (TNF-α), superoxide dismutase (SOD), and malondialdehyde (MDA). Twenty-four hours after injection of the contrast medium, the rabbits were killed and the pathological changes were observed under an electron microscope.
Results: There were statistical significances in sCr and BUN values among the four groups at both 8 hours and 24 hours after injection of the contrast medium. Serum NGAL and TNF-α levels were also significantly different among the four groups (P<0.05) 24 hours after injection of the contrast medium. The incidence rate of CIN in each group was statistically significant. Nanoliposomes had obvious advantages over hydration prevention in NGAL and TNF-α levels.
Conclusions: Nanoliposomes can prevent the occurrence of CIN and reduce the damage of contrast agent to the kidney by reducing inflammatory reaction.
Combination drug therapy prevents CIAKI by suppressing ER stress-induced apoptosis.
Wang X, Han S, Zhao L, Cong H Sci Rep. 2024; 14(1):32074.
PMID: 39738496 PMC: 11686283. DOI: 10.1038/s41598-024-83741-5.
Fu H, Wang L, Ying S, Zhao Z, Zhang P Front Cardiovasc Med. 2023; 10:1211982.
PMID: 38124888 PMC: 10731959. DOI: 10.3389/fcvm.2023.1211982.